Navigation Links
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
Date:4/24/2009

- Results inform selection of doses, regimens to be explored in Phase 2b study -

-- Phase 2b program anticipated to begin in summer 2009 --

COPENHAGEN, April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that results from a 14-day Phase 1b clinical study of ITMN-191 (R7227) in combination with the current standard of care were presented today by Stefan Zeuzem, M.D., of the J.W. Goethe University, Frankfurt, Germany, in an oral presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. The study explored the use of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin) for 14 days of treatment in hepatitis C virus (HCV) treatment-naive patients infected with HCV genotype 1. ITMN-191 is an HCV protease inhibitor being developed in collaboration with Roche.

Among the highlights of his presentation, Dr. Zeuzem reported:

  • The combination of ITMN-191 plus the standard of care for 14 days resulted in rapid and sustained reductions in HCV RNA.
  • Substantial antiviral activity was observed in both the q8h and q12h dosing cohorts; the most rapid declines in HCV RNA occurred in the ITMN-191 900 mg q12h dosing cohort.
  • Viral rebound was not observed in any patient receiving treatment with ITMN-191 plus Pegasys and ribavirin.
  • ITMN-191 plus standard-of-care therapy was safe and generally well tolerated.
  • The findings support the continued evaluation of ITMN-191-based combination regimens of twice-daily and three-times-daily dosing in patients with chronic HCV infection.

Dr. Zeuzem, protocol chair of the study, said, "Based on the t
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... DIEGO , July 25, 2014  Arena Pharmaceuticals, ... will provide a corporate update and report second quarter ... opens on Friday, August 1, 2014. That same day, ... 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... dialing 877.643.7155 for domestic callers and 914.495.8552 for international ...
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... , REDWOOD CITY, Calif. , Jan. 28 Cardica, ... second quarter and six months ended December 31, 2009 . Cardica,s ... to discuss the financial results and provide an update on the ... sales model for our cardiac anastomosis products from a direct sales force ...
... , PLEASANTON, Calif. , Jan. 28 Thoratec ... support therapies to save, support and restore failing hearts, said today that ... 2009 led to a 19 percent increase in total 2009 revenues versus ... 2, 2010 , revenues were $373.9 million versus $313.6 ...
Cached Medicine Technology:Cardica Announces Fiscal 2010 Second Quarter Financial Results 2Cardica Announces Fiscal 2010 Second Quarter Financial Results 3Cardica Announces Fiscal 2010 Second Quarter Financial Results 4Cardica Announces Fiscal 2010 Second Quarter Financial Results 5Cardica Announces Fiscal 2010 Second Quarter Financial Results 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 7Cardica Announces Fiscal 2010 Second Quarter Financial Results 8Cardica Announces Fiscal 2010 Second Quarter Financial Results 9Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 2Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 3Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 4Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 5Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 6Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 7Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 8Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 9Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 10Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 11Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 12Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 13Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 14Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 15Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 16Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 17Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 18Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 19Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 20Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 21Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 22Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 23Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009 24
(Date:7/25/2014)... UK (PRWEB) July 26, 2014 Dental ... variety of dental services including general dentistry, clear braces ... opening in September this year in Derby. The new ... at the HollyBrook Medical Centre in Littleover, Derby. Patients ... new practice. , The new dental practice, which is ...
(Date:7/25/2014)... July 26, 2014 2014 ... Gel Permeation Chromatography Industryā€¯ is a professional ... and China Gel Permeation Chromatography market. The ... including Gel Permeation Chromatography definition, classification, application, ... industry overview. This research covers the international ...
(Date:7/25/2014)... In recent years, men have become more aware of, ... associated with age-related testosterone decline. Amid concerns about testosterone and ... case study from Renew Man helps to shed light ... bioidentical hormones. , The case study centers around a patient ... beginning to feel the effects of age-related hormonal decline. ...
(Date:7/25/2014)... American motor vehicle owners who are at higher ... premiums for vehicle insurance on average. The Quotes Pros ... SR22 insurance for high risk motorists this year at ... of local agencies providing direct price quotations for risk ... available for any car owner to access. One advantage ...
(Date:7/25/2014)... As reported by the Statesman Journal in the article ... in Salem, MA as well as several other states are ... that has taken many lives during the past couple of ... which police were able to make two arrests by following ... be the victim and claiming to want to buy more ...
Breaking Medicine News(10 mins):Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Multiple States Crack Down on Heroin Epidemic 2
... be sent to manufacturers by month,s end , , FRIDAY, May ... vaccine got a bit nearer Friday, with government health officials ... such a shot. , "Today CDC received, from one institution, ... Director for Science and Public Health Program said during a ...
... statement of Matthew L. Myers, President, Campaign for Tobacco-Free ... decision by the U.S. Court of Appeals for the ... U.S. District Judge Gladys Kessler that the tobacco industry ... long campaign to defraud the American public. The Appeals ...
... give people an inventive edge , , FRIDAY, May 22 ... of the experience than a chance to visit cool museums ... sparks creativity. , Students who had lived abroad were better ... study in the May issue of the Journal of ...
... French . , Montreal, May 22, 2009 - ... its best minds in pediatric leukemia research, thanks to ... $2.5 million to support up-and-coming, Montreal-based researchers at the ... Qubec,s Institut national de la recherche scientifique Institut ...
... First Event in Year of Affordable Healthcare Roundtable SeriesSAN ... group, recently reported that healthcare premiums in California ... between 2000 and 2007. With healthcare costs continuing to ... filed, many Americans are finding themselves driven out of ...
... Venegas, M.D., has issued the,following press release: , ... been a recent flurry of panic about,the H1N1 (swine ... were cancelled. Some even suggested closing the border with ... cross back,and forth every day. The panic certainly ...
Cached Medicine News:Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 3Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 4Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 5Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 6Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 7Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 8Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 9Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 10Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 11Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 12Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 13Health News:U.S. Court of Appeals Affirms 2006 Lower Court Ruling That Tobacco Companies Committed Fraud for Five Decades and Lied About the Dangers of Smoking 2Health News:To Be More Creative, Try Living Abroad 2Health News:Cole Foundation injects $2.5 million to bolster leukemia research 2Health News:As Healthcare Costs Skyrocket, Local Leaders Gather to Seek a Solution 2Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... panel mounted system that offers several unique design ... heath care professional using the system. It ... dual action lever that allows the system to ... pole. Similarly, it features a unique squeeze-lok(tm) ...
Stylish, comfortable and attractive, the new Keeler Sport frame is available in a choice of bright colors. The Keeler Sport frame can be worn over your own glasses, or your prescription can be incorp...
Medicine Products: